Rasayana Therapeutics develops novel medicines targeting the root causes of chronic inflammatory conditions originating in the gut. The company focuses on restoring gut barrier integrity and recalibrating immune activation at the mucosal interface rather than blocking downstream cytokine signals. Their pipeline, led by an oral biologic, aims to extend human healthspan by addressing upstream immune dysregulation across the gut-organ axis.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic diseases often stem from complex interactions within the Gut-Organ Axis, a biological system that remains largely untapped for therapeutic intervention. Current approaches struggle to effectively target these intricate pathways, leading to delayed or insufficient treatment outcomes for patients.
Solution
Rasayana Therapeutics is developing novel therapeutics by focusing on the Gut-Organ Axis. The company leverages a portfolio of gut-targeted shelved assets, applying a biology-first methodology to accelerate the discovery and development of new medicines. Their lead asset, RSY-248, is a first-in-class oral biologic designed for targeted delivery within the gastrointestinal tract. By addressing the bidirectional communication between the gut and other organs, Rasayana aims to create transformative treatments for chronic conditions.
Target Audience
Rasayana Therapeutics targets pharmaceutical and biotechnology companies seeking to license or co-develop novel therapeutics for chronic diseases, as well as patients suffering from these conditions.
Features
- Focus on Gut-Organ Axis biology for chronic disease intervention.
- Utilization of a proprietary pipeline of gut-targeted shelved assets.
- Biology-first approach to drug discovery and development.
- Lead asset RSY-248: a first-in-class, gut-restricted oral biologic.
- Emphasis on bidirectional gut-organ communication pathways.